New Advanced Nailing System From DePuy Synthes Companies Designed To Improve Surgical Treatment Of Hip Fractures

LAS VEGAS, March 24, 2015 /PRNewswire/ -- DePuy Synthes Companies of Johnson & Johnson has launched the TFN-ADVANCED^™ Proximal Femoral Nailing System (TFNA), a nail, blade and screw system designed to improve patient outcomes by more closely matching the anatomy of patients undergoing hip fracture surgery. The TFNA System is featured this week by DePuy Synthes Trauma* here at the 81^st annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).

Each year, more than 1.6 million people sustain a hip fracture worldwide and it is estimated that 6.3 percent of patients undergoing surgical treatment require revision surgery.[i] Revision surgery is a second surgery that takes place if the original nail implant fails and needs to be replaced. The TFNA System helps address this issue by offering a nail designed to better fit the patient anatomy.

The LATERAL RELIEF CUT™ Design of the TFNA Nail and small diameter at the top of the nail help preserve bone and aid in ensuring a proper fit where the nail is inserted during surgery. Additionally, the TFNA Nail also has an improved overall anatomical shape that can help avoid impingement lower in the leg on the inside of the femur, an area called the anterior cortex. The curvature of the nail is based on an extensive multi-ethnic 3D computational study of femoral anatomy.

The TFNA System is made from a unique titanium alloy and incorporates a BUMP CUT™ Design that make the nail stronger than existing hip fracture nails of similar size[ii] resulting in less breakage than other commercially available nails in testing.

The Helical Blade helps the nail hold the head of the femur secure and allow proper healing. This design, proprietary to DePuy Synthes Companies, compresses bone around the implant during insertion, which may result in a more secure implant and fewer failures resulting from "cut out" of the device.  This is one of the most frequent complications associated with hip fracture nailing and often results in re-admission for revision second surgery to fix the failure.   

"A big concern, especially in elderly patients with hip fractures, is matching patient anatomy to help avoid complications such as anterior cortical impingement, and the radius of curvature of the TFNA Nail may help reduce that risk," said Christopher Finkemeier, MD, Co-Director of the Acute Care Orthopaedic Service at Sutter Roseville Medical Center and member of the AO TK Intramedullary Nailing Expert Group. "Having one system with both a screw and blade and simplified instrumentation are important for the surgeon as well. This system may help improve outcomes and minimize complications, with less time and cost in the OR."

The TFNA System features new instrumentation designed to reduce procedural complexity and offers a comprehensive range of surgical options. The fully radiolucent insertion handle provides improved x-ray visualization and features QUICK CLICK^™ Self-Retaining Technology, designed for easier attachment of the nail to the instruments. The new system also offers surgeons an extensive range of nail sizes and the choice of both a blade and screw options to suit a wide variety of clinical needs and to facilitate hospital standardization, which may help reduce costs.

"We saw an important clinical need and wanted to address it in a significant way," said I.V. Hall, Franchise Unit Leader, DePuy Synthes Trauma. "We looked at every aspect of nail design and instrumentation, and considered input from hundreds of surgeons, hospitals and academic institutions worldwide. We then took all this data, our vast experience in designing some of the world's leading trauma systems and developed the TFNA System, which has the potential to improve patient outcomes, improve efficiency in the operating room, help reduce costs and increase patient satisfaction."

Complementing this new product offering is the Geriatric Fracture Program. This initiative is part of

DEPUY SYNTHES ADVANTAGE™, which offers customized, measurable solutions that help achieve triple aim performance – improved outcomes, increased patient satisfaction, and reduced cost.  The Geriatric Fracture Program provides a standard team-based approach to treating patients undergoing surgery for hip fracture from the time they arrive in the emergency department through discharge. This approach helps patients get back to their pre-injury status faster. In addition, a subscription-based software solution called CareSense enables health care providers and institutions to collect and analyze real-time data to help optimize care for these patients.

By offering the TFNA system, as well as programs like the Geriatric Fracture Program and CareSense, DePuy Synthes is providing customers with a range of solutions to help them better treat their hip fracture patients.

DePuy Synthes Companies
DePuy Synthes Companies provides the most comprehensive orthopaedic and neurological solutions in the world. The company offers an unparalleled breadth of products, services, programs and research and development capabilities. DePuy Synthes Companies' solutions in the specialties of joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

Note on Forward-Looking Statements
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Orthopaedics, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; competition, including technological advances, new products and patents attained by competitors; global health care reforms and trends toward health care cost containment; product recalls or regulatory action; and manufacturing difficulties and delays. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Orthopaedics, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.)

*A division of DePuy Orthopaedics, Inc.
©DePuy Synthes 2015. All rights reserved. 

DSUS/TRM/0315/0549 03/15

[i] Parker, M.J. and H.H. Handoll, Gamma and other cephalocondylic intramedullary nails versus extramedullary implants for extracapsular hip fractures in adults. Conchrane Database Syst Rev, 2010 (9): p. CD000093.

[ii] Data on file at DePuy Synthes, Bench/Animal Test results may not necessarily be indicative of clinical performance.

SOURCE DePuy Synthes Companies